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Abstract
Objective: To examine potential correlations between 
maternal serum placental protein-13 (PP-13) and first trimes-
ter maternal and placental factors, and to evaluate the asso-
ciation of this marker with adverse pregnancy outcome.
Methods: Serum samples from prospectively enrolled 
patients between 11 and 13 weeks and 6  days were ana-
lyzed for PP-13 using an ELISA assay. The relationships 
between maternal serum PP-13 levels and gestational 
age, maternal age, ethnicity, parity, smoking status, body 
mass index (BMI), mean arterial blood pressure, uterine 
and umbilical artery Doppler parameters were examined. 
The association between first-trimester PP-13 levels and 
subsequent pre-eclampsia and delivery of a small for ges-
tational age (SGA) neonate was also investigated, after 
excluding patients who received aspirin.
Results: In 908 patients, PP-13 levels ranged from 8.0 
to 537.5  pg/mL. A significant negative correlation was 
identified between PP13 and BMI (Spearman rho –0.20, 
P < 0.0001). Smoking significantly decreased PP-13 (P < 0.01). 
No relationship was identified with the other parameters. 
In a subgroup of 668 low-risk patients who did not receive 
aspirin, PP-13 levels were not associated with development 
of pre-eclampsia, SGA or the combination of them.
Conclusion: First-trimester PP-13 levels are significantly 
correlated with BMI and smoking. These correlations 
appear independent of uterine and umbilical artery resist-
ance. In low risk patients, PP-13 levels fail to predict the 
risk for pre-eclampsia or SGA.
Keywords: Fetal Doppler ultrasound; placenta; PP-13; 
 pre-eclampsia; SGA; small-for-gestational age.
Introduction
In normal pregnancy, early placental growth, angio- 
neogenesis and synthesis of trophic substances are impor-
tant for physiologic changes that can be observed in the 
mother, placenta and fetus as early as 8–12 weeks’ gesta-
tion [1]. There is a significant decline in mean arterial pres-
sure, decreasing blood flow impedance in the uterine and 
umbilical arteries, and exponential placental and fetal 
growth. Abnormalities in this early placental develop-
ment lead to incomplete physiological adaptation and are 
precursors of placental dysfunction placing women at risk 
for hypertensive gestational disorders and fetal growth 
restriction [2, 3]. Identification of markers of suboptimal 
early placental development opens possibilities for an 
integrated screening approach. In this context it has been 
demonstrated that the combination of maternal factors, 
biochemical markers and ultrasound evaluation offers 
superior prediction but requires careful consideration 
of interactions in the construction of a screening model 
[4, 5]. Accordingly, recognition of interactions between 
first-trimester markers is important in the construction of 
effective risk prediction strategies.
Placental protein 13 (PP-13) is a 32-kDa protein located 
in the brush border at the maternal-fetal interface of 
the syncytiotrophoblast layer that is involved in pla-
cental implantation and spiral artery remodeling [6, 7]. 
Decreased levels and impaired responsiveness to PP-13 
are thought to play a role in the pathogenesis of placental 
dysfunction [8, 9]. While several screening studies have 
demonstrated significantly lower levels of PP-13 in the first 
trimester in pregnancies with subsequent pre-eclampsia 
Brought to you by | Johns Hopkins University
Authenticated
Download Date | 6/14/16 3:39 PM
2      Seravalli et al., PP-13, maternal characteristic and pregnancy outcome
and fetal growth restriction [3, 6, 10–15], some other 
reports failed to find such association [16–19]. In these 
studies, predictive accuracy varied among ethnic groups, 
patient demographics, and case control studies. In addi-
tion, maternal factors such as the ABO blood type appear 
to affect measurements of PP-13 concentration [20]. In 
view of these findings it was the aim of this study to evalu-
ate the relationships between PP-13 levels and maternal 
and placental factors in the first trimester of pregnancy 
and to determine the association with adverse pregnancy 
outcome in women who did not receive aspirin treatment 
in pregnancy.
Materials and methods
Study population and design
This is a nested multi-site prospective observational study of women 
with a singleton gestation presenting for first-trimester screening at 
four hospitals in the Baltimore metropolitan area between 2007 and 
2010. The protocol was approved by the Institutional Review Boards 
of each participating center. Ethical review was not required for this 
study. On arrival to the fetal medicine unit, all patients were informed 
about the study and after the first-trimester ultrasound confirmed a 
live singleton intrauterine pregnancy at 11 weeks and 0 day to 13 weeks 
and 6 days gestational age, a request was made to join the study.
After written informed consent, maternal demographics, medi-
cal and obstetric history and self-reported smoking status were 
recorded. Gestational age was calculated from the last menstrual 
period and confirmed by ultrasound crown-rump length (CRL) meas-
urement. Doppler ultrasound of the maternal uterine and fetal umbil-
ical arteries was performed using the trans-abdominal approach. The 
uterine artery Doppler waveform was assessed semi-quantitatively 
using the pulsatility index (PI) and qualitatively for the presence of a 
diastolic notch. The umbilical artery Doppler waveform was also ana-
lyzed using the PI and noting the presence of forward end diastolic 
velocity. Ultrasound output was set to yield thermal and mechanical 
index values below 0.8 in the region of interest, following the as low 
as reasonably achievable (ALARA) principle [21].
After completion of the ultrasound examination, maternal 
height and weight were measured. Following seated rest for 5  min 
a single automated blood pressure measurement was obtained 
(Dinamap Pro1000, General Electric Medical Systems, Milwaukee, 
WI, USA). For this measurement the cuff size was adjusted to the 
maternal arm circumference and the arm was supported at the level 
of the heart. The mean arterial blood pressure [MAP = (systolic blood 
pressure+2 × diastolic blood pressure)/3] was calculated.
All values were entered into a database under the assigned 
unique patient identifier. A 5 ml blood sample was then collected into 
a serum separation tube using occlusive venipuncture. The tubes 
were marked with the patient identifier, centrifuged at 8000 rpm for 
15 min and stored at −4°C within 60–90 min of the blood draw and 
stored at −80°C in 1 cc aliquots.
Pregnancy outcome and corresponding source documentation 
was collected by study personnel. Cases of spontaneous or therapeutic 
abortion, intrauterine demise, major fetal anomaly or aneuploidy 
were excluded from the analysis. Delivery circumstances, birth-
weight and birth-weight percentile were ascertained. Small for gesta-
tional age (SGA) neonates were defined as those having a birth-weight 
(BW) below the 10th percentile by reference standards. Pre-eclampsia 
was defined as hypertension (systolic blood pressure  ≥ 140 mm Hg or 
diastolic blood pressure  ≥ 90 mm Hg) on at least two occasions, 6 h 
to 7 days apart, in a woman with previously normal blood pressure, 
associated with proteinuria ( > 300 mg protein in 24 h collected urine, 
without prior proteinuria) after 20 weeks of gestation [22].
PP-13 immunoassay
Frozen stored serum samples were thawed slowly and brought 
to room temperature for examination by a solid-phase sandwich 
enzyme-linked immunosorbent assay (ELISA). They were diluted 
1:3 and overlaid onto a 96-well microplate coated with PP13 spe-
cific mouse mono-clonal antibody (MAb) and incubated overnight 
at room temperature. The microplates were then washed and the 
complex was marked with a second PP13 specific MAb conjugated 
with biotin. The complex was amplified with the biotin-extravidin-
horseradish-peroxidase complex. The assay was then developed 
with tetra-methyl-benzidine substrate, as previously described 
[9]. The optical density was measured at 450 nm against a 650 nm 
background. Concentrations were determined by extrapolation from 
a standard curve constructed using recombinant PP-13 standards 
(0–400 pg/mL). The laboratory staff performing the PP-13 assays 
had only sample codes and was blinded to pregnancy outcome. Both 
sonographers, who acquired the Doppler measures, and physicians, 
who observed the patients, were blinded to the results of PP-13 assays 
to avoid any observer bias. The performance of PP-13 ELISA kit and 
assay were previously assessed in a validation study on samples from 
56 pregnant and 56 non-pregnant patients. Samples were tested in 
duplicates. The specificity of the assay was 90.5%. The coefficients 
of variation (CV) were set sequentially to fit the following PP-13 val-
ues:  < 9% for PP13 above 25 pg/mL, up to 16% for PP13 between 12.5 
and 24.9 pg/mL and up to 23% for PP13 values below 12.5 pg/mL. At 
this level, the optical density (OD) was 0.01–0.04 OD and therefore 
0.01 OD unit difference corresponds to 20% CV which is only up to 
1 pg/mL PP13.
Statistical analysis
The relationships between maternal serum levels of PP-13 and gesta-
tional age, maternal age, ethnicity, parity, smoking, body mass index 
(BMI), mean arterial blood pressure (MAP), uterine and umbilical 
Doppler parameters were examined. All Doppler indices were con-
verted into z-scores using reference values derived from pregnan-
cies with documented normal outcome from our study cohort. The 
relationship of PP-13 levels with gestational age and maternal char-
acteristics was explored using a non-parametric correlation analysis 
(Spearman’s coefficient), since neither raw nor log-transformed PP-13 
values fitted a Gaussian distribution.
In order to evaluate the correlation with pregnancy outcomes, 
the measured PP-13 concentrations were then converted into mul-
tiples of the median (MoM). A Mann-Whitney test was used to esti-
mate the association between first-trimester PP-13 MoM and: a) 
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arterial blood pressure. PP-13 levels showed a significant 
negative correlation with BMI (Spearman’s rho –0.20, 
P < 0.0001) and a weaker positive correlation with mater-
nal age (Spearman’s rho 0.11, P = 0.001). Similarly, women 
with a BMI greater 30 kg/m2 had significantly lower PP-13 
levels, and advanced maternal age was associated with 
higher values (P < 0.01) (Table 3). The correlation with 
BMI was stronger in Caucasian than in African-American 
development of pre-eclampsia, b) delivery of an SGA neonate and c) a 
composite outcome of pre-eclampsia or SGA, after excluding patients 
who received aspirin or enoxaparin in pregnancy. At our Institutions 
aspirin treatment is initiated in the first trimester in patients con-
sidered at high risk for pre-eclampsia or intrauterine growth restric-
tion based on obstetric history (previous pre-eclampsia or SGA), 
first-trimester maternal characteristics (chronic hypertension, pre- 
gestational diabetes, high BMI) and the presence of bilateral notch in 
first-trimester uterine artery Doppler [23].
Statistical analysis was performed with SPSS 20.0 (SPSS Inc, 
Chicago, IL, USA). A P-value  < 0.05 was considered statistically sig-
nificant.
Results
A total of 942 patients were consecutively enrolled. Of 
these, 34 met one of the exclusion criteria. The character-
istics of 908 women included in the analysis are reported 
in Table 1. The mean gestational age at enrollment was 
12.6 weeks. The median maternal age was 31  years and 
women were predominantly of Caucasian or African-
American ethnicity. Over one third of women were nul-
liparous. Pre-existing medical conditions were infrequent 
and 53 (5.8%) women reported pre-eclampsia or intrau-
terine growth restriction (IUGR) in a previous pregnancy. 
Tobacco use was reported in 9.4% of patients. At first-tri-
mester enrollment, 30% of women met criteria for obesity 
and 36 women (4%) had a mean arterial pressure above 
100 mm Hg. The mean uterine artery PI z-score was 0.16 
(IQR –0.60, 0.88) and bilateral notching was observed in 
30% of women. Umbilical artery end-diastolic velocity 
was present in the majority of fetuses (619, 68.2%).
The median concentration of PP-13 was 73.7  pg/mL 
(IQR: 47.8–111.1 pg/mL). The median levels for each ges-
tational week are reported in Table 2. The levels showed 
a weak correlation with gestational age (Spearman’s 
rho –0.07, P = 0.04).
Relationship between PP-13 levels and  
first-trimester parameters
No association was found between first-trimester PP-13 
concentrations and maternal ethnicity, parity or mean 
Table 1: Characteristics of the study population at enrollment.
Demographic and obstetric characteristics   n = 908
Maternal characteristics
 Age   31 (25, 36)
 Advanced maternal age( > 35 year)   308 (33.9%)
 Ethnicity  
  African American   404 (44.5%)
  Caucasian   432 (47.6%)
  Hispanic   53 (5.8%)
  Other   19 (2.1%)
Pre-existing conditions
 Tobacco use   85 (9.4%)
 Diabetes mellitus   42 (4.6%)
 Hypertension   79 (8.7%)
Obstetrical history
 Nulliparity   370 (40.7%)
 Prior pre-eclampsia   49 (5.4%)
 Prior IUGR   4 (0.4%)
Gestational age at examination (weeks)   12.6 (12.1, 13.0)
First trimester maternal physical examination
 Body mass index (kg/m2)   26.2 (22.7, 31.4)
 Body mass index  ≥ 30 kg/m2   275 (30.3%)
 Systolic blood pressure (mm Hg)   114 (106, 123)
 Diastolic blood pressure (mm Hg)   67 (63, 72)
 Mean arterial blood pressure (mm Hg)   82.7 (78.0, 88.3)
 Mean arterial blood pressure  > 100 mm Hg  36 (4.0%)
First trimester ultrasound examination
 Mean uterine artery PI z-score   0.16 (–0.60, 0.88)
 Bilateral notching   274 (30.2%)
 Umbilical artery PI z-score   –0.14 (–0.71, 0.42)
 Umbilical artery end-diastolic velocitya  
  Present   619 (68.2%)
  Absent   238 (26.2%)
Data are given as n (%) or median and interquartile range (IQR, 
25th–75th percentile).
IUGR = Intrauterine growth restriction.
aMissing value in 51 patients.
Table 2: Distribution of placental protein 13 levels (pg/mL) throughout gestational age.
Gestational week   n  Median PP-13 level (pg/mL)  Interquartile range (25th–75th percentiles)
11 weeks and 0 day to 11 weeks and 6 days  137  72.2  52.9, 110.6
12 weeks and 0 day to 12 weeks and 6 days  531  76.9  48.1, 112.7
13 weeks and 0 day to 13 weeks and 6 days  240  69.5  43.7, 105.9
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women (Spearman’s rho –0.23 and –0.14, respectively). 
Cigarette smoking was associated with a profound 
decrease in PP-13 levels (P < 0.01). First-trimester placental 
blood flow studies did not show any significant relation-
ship with PP-13 values.
A multivariate linear regression analysis was then 
performed to determine the independence and relative 
contribution of variables identified as significant in the 
correlation analyses. After linear regression analysis, only 
BMI and smoking were found to be independent predic-
tors of PP-13 concentration, while maternal age and gesta-
tional age showed no effect.
Relationship between PP-13 levels and 
outcome
After exclusion of 240 women that received first-trimester 
aspirin, the association between first-trimester PP-13 con-
centrations and pre-eclampsia or SGA was evaluated in 
668 women considered at low-risk for placenta-related 
diseases. The incidence of pre-eclampsia and small for 
gestational age in this group was 3.3% and 6.4%, respec-
tively. Maternal characteristics, delivery outcome and 
PP-13 levels are described in Table 4. In order to evaluate 
the correlation with pregnancy outcomes, the measured 
PP-13 concentrations were converted into multiples of the 
median (MoM) corrected for maternal BMI. No signifi-
cant association was found between first-trimester PP-13 
MoM and development of pre-eclampsia, SGA or a com-
posite outcome of pre-eclampsia or SGA (P = 0.99, P = 0.72, 
P = 0.46) (Figure 1). Even when the analysis was limited to 
cases of severe SGA with a birth-weight  < 5th percentile, no 
difference was found in the levels of PP-13 compared to 
controls.
Discussion
The aims of this study were to determine the relation-
ship between maternal and placental characteristics and 
serum PP13 levels in the first trimester and further to test 
the relationship between PP13 levels and adverse outcome 
in low-risk women. First-trimester PP-13 correlated nega-
tively with maternal BMI and was profoundly decreased 
by maternal smoking. In contrast, no relationship was 
observed with maternal blood pressure or Doppler param-
eters of the uterine and umbilical arteries. In low-risk 
patients PP-13 did not predict placenta-related disease at 
birth.
Recognition of interactions between first-trimester 
biomarkers and patient characteristics is important in the 
construction of effective risk assessment strategies.
In most studies, absolute PP-13 levels were converted 
to gestational week- specific multiples of the median 
(MoM), which in some cases were further adjusted for 
maternal age, weight, smoking or ethnicity [3, 11, 16]. 
These adjustments, however, are not uniform between 
studies. In the study by Nicolaides et  al. [10], PP-13 was 
not significantly associated with maternal age, parity or 
weight. Similarly, Chafetz et al. [6] found no association 
between PP-13 levels and maternal age, ethnicity, arterial 
blood pressure or maternal BMI among controls. Conse-
quently, no adjustments for these variables were made. 
On the other hand, and in accordance to our results, other 
studies found a significant inverse correlation between 
PP-13 and a) maternal BMI or weight [3, 11, 16, 24] and b) 
tobacco use in unaffected controls [16, 24]. These find-
ings suggest that there is heterogeneity in the relationship 
between PP-13 and maternal characteristics across differ-
ent populations and that the adjustment of MoM levels 
may not be uniformly applicable.
Table 3: Distribution of placental protein 13 levels (pg/mL) in relation to maternal characteristics, uterine and umbilical artery Doppler 
parameters.
Variable   No   Yes   P-value
Advanced maternal age ( > 35 years)   68.6 (44.1, 107.4)   83.5 (53.0, 120.4)    < 0.01
African-American ethnicity   77.6 (48.1, 116.5)   70.9 (47.4, 105.4)   0.07
Nulliparity   74.9 (44.7, 109.8)   72.4 (49.4–111.8)   0.37
Tobacco use   76.9 (49.9, 113.4)   49.9 (31.7,88.2)    < 0.01
BMI  > 30 Kg/m2   80.7 (51.6, 120.1)   61.7 (38.1, 92.9)    < 0.01
First trimester MAP > 100 mm Hg   74.0 (47.9, 111.1)   66.2 (35.0–115.2)   0.49
Bilateral notching   73.4 (47.8, 110.3)   74.2 (47.4, 111.8)   0.77
Umbilical artery absent end-diastolic flow  73.2 (44.8, 110.7)   78.8 (53.8, 115.0)   0.10
PP-13 levels are given as median and interquartile range (IQR, 25th–75th percentile).
All tests are Mann-Whitney-U.
BMI = Body mass index, MAP = mean arterial blood pressure.
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In the absence of a large multimarker cohort study, 
it is difficult to ascertain the reason for the inverse cor-
relation between PP-13 and BMI. A possible explanation 
is to consider the placenta as the single source of PP13, 
with the BMI having a dilutional effect. However, other 
mechanisms are possible. Body mass index elevation is 
one of the components of the metabolic syndrome that is 
associated with placental disfunction. It is possible that 
lower PP-13 levels in women with increasing BMI could 
be a reflection of early placental dysfunction produced by 
metabolic risk factors [25]. Clarification of the underlying 
mechanism is important to determine if BMI adjustement 
is appropriate.
The lack of a correlation between PP-13 levels and 
uterine artery Doppler characteristics in our population 
indicates an independent role of these two markers. This 
can be explained by the fact that uterine artery veloc-
ity waveform and serum biomarkers such as PP-13 and 
PlGF reflect different vascular areas, and therefore are 
independent of each other [26]. Their use in combina-
tion in a contingent screening for pre-eclampsia has 
been suggested [10]. In a large study by Odibo et al. [13], 
however, combinations of two or more of the first-trimes-
ter markers (PP-13, PAPP-A and uterine artery Doppler) 
failed to yield an improvement above single marker 
sensitivity for the prediction of pre-eclampsia [13]. This 
likely reflects that some of the parameters studied (e.g. 
PP-13 and PAPP-A) are involved in the same pathway of 
maternal decidual modification in early pregnancy [13]. 
Similarly, measurement of serum PP-13 in the first trimes-
ter appeared not to improve the performance of screen-
ing for early pre-eclampsia achieved by a combination 
of maternal factors, uterine artery PI and serum PAPP-A 
in a case control study including 208 cases that devel-
oped pre-eclampsia [24]. However, there are also studies 
in which PP13 and mean arterial pressure [27], PP13 and 
PlGF [14] and PP13 with Doppler [28] showed improved 
prediction.Ta
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Figure 1: Box plots display of PP-13 MoM as a function of preec-
lampsia and SGA. (SGA = Small for gestational age.)
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When we looked at the ability of PP-13 to predict pre-
eclampsia or SGA in a population considered at low risk 
for placental-related disease, we were unable to find any 
significant correlation between first-trimester levels of this 
marker and the outcomes investigated. Previous studies 
on the predictive properties of PP-13 for pre-eclampsia and 
SGA yielded conflicting results. While some studies found 
significantly lower first-trimester levels of PP-13 in preg-
nancy complicated by pre-eclampsia [3, 6, 10, 12–14, 29] 
or SGA [6, 15, 29] suggesting a potential incorporation of 
this biomarker in the risk assessment for pre-eclampsia, 
especially for the early-onset form [3, 10], other cohorts 
and case-control studies failed to find such associations 
[16–19]. Moreover, even when a significant association is 
found, the predictive accuracy varies, with some studies 
showing promising results [3, 6, 10–12] and others showing 
less remarkable predictive properties [13–15, 24, 29]. In 
their systematic review and meta-analysis of 8 studies, 
Schneuer et al. reported sensitivity rates of 24% and 45% 
for pre-eclampsia and early-onset pre-eclampsia, respec-
tively, at 5% false positive rate [29]. In a more recent meta-
analysis of 19 studies, the detection rate ranged from 47% 
for all cases of pre-eclampsia to 83% for early cases alone, 
at a 10% false positive rate [30]. A possible explanation 
of the difference among studies is the variation in study 
design, numbers of cases, employed assay, and the char-
acteristics of the study population [29]. Our study differs 
from previous reports because we excluded patients who 
received aspirin, who were considered at high risk for pre-
eclampsia based on history or first-trimester screening. 
For this reason, our results suggest that while PP13 may 
be a statistically valid cofactor in an unselected popula-
tion, it does not have sufficient independent discrimina-
tory power in women at low risk for pre-eclampsia. It is 
unclear if this is due to the heterogeneity of first-trimester 
associations between first-trimester PP-13 and maternal 
variables in different study populations or due to vari-
ability in the association with outcome. Recently, single 
nucleotide polymorphism of the PP-13 sequence was 
determined between White and Black British women in 
the United Kingdom and also between South African and 
British Black women, providing additional explanation 
for study result diversity (Meiri et al., 14th World Congress 
in Fetal Medicine, 2015).
The median PP-13 concentrations found in our cohort 
are consistent with those reported in previous studies, 
where PP-13 median levels range from 53 to 66 pg/mL in the 
control group [16, 24, 29, 31]. The wide range of variation 
observed in PP13 levels probably reflects the diversity of 
this protein release from the placenta to the maternal blood 
and the potential various factors influencing this release.
One possible limitation of our study is that we used 
the automated ELISA method for the quantification of 
PP-13, while the newest AutoDELFIA technique has been 
recently reported to be a more robust and reproducible 
assay than the ELISA [32]. However, ELISA technique has 
been demonstrated to have a better clinical discrimina-
tion between PP-13 levels in cases of pre-eclampsia and in 
controls [32], and it has been employed in numerous pre-
vious studies. Further studies are needed to compare the 
performance the two assays.
In conclusion, first-trimester PP-13 levels show signifi-
cant correlation with BMI, a maternal risk factor for subse-
quent placental dysfunction, and with tobacco use. These 
relationships appear independent of uterine or umbilical 
artery Doppler. In a population at low risk for pre-eclampsia 
by first-trimester screening, PP-13 levels failed to indepen-
dently identify women at risk for placental dysfunction.
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